https://www.selleckchem.com/pr....oducts/Abitrexate.ht
Among the 805 patients, 195 were found to have only VUS and no pathogenic variants (PV), and 41.5% (81/195) were reclassified as benign or likely benign, and 10.3% (20/195) as pathogenic or likely pathogenic variants. Approximately 33.3% (36/108) of the specific variants analyzed in this study that were initially classified as VUS over a 13-year period were reclassified. Among these, 5.6% (6/108) were reclassified as pathogenic or likely pathogenic variants. Approximately 33.3% (36/108) of the specific BRCA1/2 variants analyzed in th
Like
Comment
Share
